Monday, August 31, 2026

Microsoft’s Copilot Takes Center Stage as Nadella Pushes Korea AI Plans

Microsoft CEO Satya Nadella discusses AI's impact on industries and introduces Copilot, enhancing user experiences and productivity.

North Korea Turns to Science for Farming Solutions Amid Food Crisis

This year, North Korea has again called on agricultural workers to implement measures to ensure crops' safe and scientific growth.

Electric Scooters Account for 77% of Battery Fire Incidents Nationwide

Jangheung Fire Station warns against charging e-scooters and phones in unsafe areas due to rising battery fire incidents.

Tag: Samsung Bioepis

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Samsung Bioepis, Built on Biosimilars, Expands Growth Strategy Into Novel Drugs

Samsung Bioepis is pursuing a two-track growth strategy that combines global biosimilar expansion with next-generation novel drug development, including ADC therapies.

AI-Powered Antibody Drug Development: Samsung Biologics and Protina’s Game-Changing License Agreement

Samsung Bioepis and Protina sign a licensing agreement to develop AI-designed antibody drugs, aiming for candidates by 2027.

Samsung Bioepis Signs Teva Deal to Commercialize Opuviz in Canada, Expanding North American Biosimilar Business

Samsung Bioepis partners with Teva to launch ophthalmology biosimilar Opuviz in Canada, enhancing access to treatments for patients.

Unlocking Cancer Treatment: Samsung Bioepis Achieves Keytruda Biosimilar Equivalence in Global Trials

Samsung Bioepis' biosimilar SB27 shows equivalence to Keytruda in key clinical trials, enhancing access to cancer immunotherapy.

Samsung Bioepis Launches SBE303: The First ADC Drug Candidate Targeting Nectin-4 in Cancer Trials

Samsung Bioepis has begun Phase 1 trials for its ADC candidate SBE303, targeting solid tumors, set to continue until July 2030.

Samsung Bioepis Expands SB15 Eylea Rival: Licensing Pact Targets Global Markets as Original Drug Hits $10.5B Sales

Samsung Bioepis has secured a licensing deal for its ophthalmic treatment SB15, expanding access in international markets outside the US and Canada.

Samsung Bioepis Taps Harrow to Take Over U.S. Ophthalmic Drug Rights from Biogen

Samsung Bioepis partners with Harrow to sell ophthalmic treatments in the U.S., transferring rights from Biogen by 2025.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.